SCHEMBL1911986

SCHEMBL1911986

COc1cc(N2CCOCC2)ccc1Nc1ncc(Br)c(Nc2ccccc2C)n1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 4/20 0.75
ALK Q9UM73 4/20 0.69
INSR P06213 3/20 0.69
LRRK2 Q5S007 5/20 0.64
EGFR P00533 3/20 0.63
IGF1R P08069 2/20 0.63
ZAP70 P43403 2/20 0.63
CAMKK2 Q96RR4 2/20 0.62
MAPK8 P45983 2/20 0.62
MAPK9 P45984 2/20 0.62
MAPK10 P53779 2/20 0.62
GSK3A P49840 1/20 0.62
MAPK15 Q8TD08 1/20 0.62
CDK2 P24941 2/20 0.62
PTK2 Q05397 2/20 0.62
DCLK1 O15075 2/20 0.62
CDC7 O00311 1/20 0.62
PLK4 O00444 1/20 0.62
CHEK1 O14757 1/20 0.62
AURKA O14965 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1912108 0.91 ULK1 (0.64) ULK1ALKINSRLRRK2EGFR
SCHEMBL18650996 0.90 ALK (0.85) ALKINSRLRRK2EGFRIGF1R
SCHEMBL31251193 0.87 ALK (0.83) ULK1ALKINSRLRRK2EGFR
SCHEMBL375608 0.86 ULK1 (1.00) ULK1ALKINSRLRRK2EGFR
SCHEMBL17547465 0.86 ULK1 (1.00) ULK1ALKINSRLRRK2EGFR
SCHEMBL29900883 0.86 ULK1 (1.00) ULK1ALKINSRLRRK2EGFR
SCHEMBL31174596 0.85 ULK1 (0.87) ULK1ALKINSRLRRK2EGFR
SCHEMBL12312367 0.85 ULK1 (0.81) ULK1ALKINSRLRRK2EGFR
SCHEMBL12780630 0.84 ULK1 (0.65) ULK1ALKINSRLRRK2EGFR
SCHEMBL12780549 0.84 ULK1 (0.84) ULK1ALKINSRLRRK2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660458-B1 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS NOVARTIS AG (CH) 2012-01-25 EP disclosed
EP-2287156-A1 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders Novartis AG (CH) 2011-02-23 EP disclosed